ConductScience.org, home
Papers
API referenceFor AI assistants

Paper · 29436178

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.

Vanderwalde A and 4 others. Cancer Med, 2018. Cited by 386 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients. Papers, record 29436178. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/29436178

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients.
PubMed
Journal
Cancer Med
PubMed
Year
2018
PubMed
Publication types
Journal Article, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
386
iCite
Relative citation ratio, by iCite
11.9
iCite
Revised in PubMed
2022-04-09
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vanderwalde AAri
2Spetzler DDavid
3Xiao NNianqing
4Gatalica ZZoran
5Marshall JJohnhttps://orcid.org/0000-0002-3449-2344

Source PubMed

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
B7-H1 AntigenMajor topic
High-Throughput Nucleotide SequencingMajor topic
Microsatellite InstabilityMajor topic
Tumor BurdenMajor topic
Female
Humans
Male
Mutation
Retrospective Studies

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Erratum in29,924,501Corrigendum.https://conductscience.org/library/papers/29924501

Source PubMed

References23

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
126,412,456Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.N Engl J Med2015https://conductscience.org/library/papers/26412456PubMed
226,432,245A global reference for human genetic variation.Nature2015https://conductscience.org/library/papers/26432245PubMed
326,952,546Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.Lancet2016https://conductscience.org/library/papers/26952546PubMed
428,420,421Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden.Genome Med2017https://conductscience.org/library/papers/28420421PubMed
527,412,392Mismatch Repair Deficiency and Response to Immune Checkpoint Blockade.Oncologist2016https://conductscience.org/library/papers/27412392PubMed
627,694,933Classification and characterization of microsatellite instability across 18 cancer types.Nat Med2016https://conductscience.org/library/papers/27694933PubMed
725,765,070Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.Science2015https://conductscience.org/library/papers/25765070PubMed
817,460,459Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma.Am J Surg Pathol2007https://conductscience.org/library/papers/17460459PubMed
927,001,570Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency.J Clin Oncol2016https://conductscience.org/library/papers/27001570PubMed
1016,825,502Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers.J Mol Diagn2006https://conductscience.org/library/papers/16825502PubMed

1 to 10 of 23

See all 23 references

Cited by273

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 386 citations.

PMIDTitleJournalYearIn PapersSource
42,894,251New perspective on epigenetic modification and immunotherapy in endometrial cancer.Clin Epigenetics2026https://conductscience.org/library/papers/42894251PubMed
42,679,811Integrated clinicogenomic analysis reveals the evolution and metastatic tropisms of advanced colorectal cancer.Cancer Cell2026https://conductscience.org/library/papers/42679811PubMed
42,430,699Long-Term Outcomes and Surgical Conversion After Immunotherapy in Microsatellite Instability-H Biliary Tract Cancers.JCO Precis Oncol2026https://conductscience.org/library/papers/42430699PubMed
42,351,461Genomic Instability Score Across Diverse Tumor Types Using the Illumina TruSight Oncology 500 HRD Assay.Diagnostics (Basel)2026https://conductscience.org/library/papers/42351461PubMed
42,286,843Comprehensive Genomic Profiles of Patients With Biliary Tract Cancer.Cancer Med2026https://conductscience.org/library/papers/42286843PubMed
42,165,902Microsatellite instability and mismatch repair deficiency prevalence among Hispanic/Latino individuals with colorectal cancer: a systematic review and meta-analysis.Int J Colorectal Dis2026https://conductscience.org/library/papers/42165902PubMed
41,948,196CXCR4 mRNA overexpression: an indicator of poor survival and predictor of response to immune checkpoint inhibitors in patients with metastatic colorectal cancer.BMJ Oncol2026https://conductscience.org/library/papers/41948196PubMed
41,895,280Cancer type-specific variation in patterns of driver alterations across 50,000 tumors.Cancer Cell2026https://conductscience.org/library/papers/41895280PubMed
41,812,316Somatic and germline genomic variation in thymic carcinomas.ESMO Open2026https://conductscience.org/library/papers/41812316PubMed
41,781,908Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1).BMC Cancer2026https://conductscience.org/library/papers/41781908PubMed

1 to 10 of 273

See all 273 cited by

Genes6

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CD27429,126PubTator's text mininghttps://conductscience.org/library/genes/29126NCBI Gene
CTLA41,493PubTator's text mininghttps://conductscience.org/library/genes/1493NCBI Gene
MLH14,292PubTator's text mininghttps://conductscience.org/library/genes/4292NCBI Gene
MSH24,436PubTator's text mininghttps://conductscience.org/library/genes/4436NCBI Gene
MSH62,956PubTator's text mininghttps://conductscience.org/library/genes/2956NCBI Gene
PMS25,395PubTator's text mininghttps://conductscience.org/library/genes/5395NCBI Gene

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/29436178

GET https://conductscience.org/api/papers/v1/29436178/references?page=2

API referenceFor AI assistants